Abecma

Abecma, also known by its development name idecabtagene vicleucel, is a BCMA-directed autologous CAR-T cell therapy for adults with multiple myeloma that is relapsed or refractory after multiple prior therapies. It was approved by the U.S. Food and Drug Administration in 2021 for patients who have received at least four prior lines of therapy and have disease progression after the last therapy. Regulatory status outside the United States varies by region.

Abecma is built from the patient’s own T cells. Those cells are collected by leukapheresis, genetically modified to express a chimeric antigen receptor targeting BCMA, and expanded in the laboratory. After a lymphodepleting conditioning regimen, the engineered cells are infused back into the patient as a single dose. Because the therapy is personalized, manufacturing and logistics can affect the time to treatment.

Administration requires careful setting and monitoring due to risks such as cytokine release syndrome (CRS) and neurologic toxicities. Patients typically receive a conditioning regimen prior to infusion and are observed closely for adverse events after infusion. Abecma is approved with a risk evaluation and mitigation strategy (REMS) program to ensure proper handling, patient education, and management of potential toxicities.

Common adverse events include CRS, neurotoxicity, cytopenias, infections, and fatigue. Serious events can occur, necessitating prompt medical management and access to specialized care. Efficacy data from clinical trials demonstrated meaningful responses in a population with limited treatment options, contributing to its regulatory approval and use in eligible patients.